Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sonnet BioTherapeutics Holdings, Inc.

1.23
-0.0650-5.02%
Post-market: 1.230.00000.00%16:47 EDT
Volume:46.39K
Turnover:57.33K
Market Cap:3.77M
PE:-0.17
High:1.29
Open:1.29
Low:1.21
Close:1.30
Loading ...

Sonnet Biotherapeutics Holdings Inc Qtrly Loss per Share $1.56

THOMSON REUTERS
·
13 Feb

Sonnet Biotherapeutics Holdings Inc: Jay Cross Resigns as CFO, Effective Feb 21, 2025

THOMSON REUTERS
·
13 Feb

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

GlobeNewswire
·
13 Feb

Sonnet Biotherapeutics Holdings Inc expected to post a loss of $1.39 a share - Earnings Preview

Reuters
·
10 Feb

BRIEF-Sonnet Biotherapeutics Further Expands Global Intellectual Property Portfolio With Issuance Of EU Patent For Fhab® Platform Technology

Reuters
·
29 Jan

Sonnet BioTherapeutics further expands global IP portfolio

TIPRANKS
·
28 Jan

Sonnet Biotherapeutics Further Expands Global Intellectual Property Portfolio With Issuance of EU Patent for Fhab® Platform Technology

THOMSON REUTERS
·
28 Jan

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

GlobeNewswire
·
28 Jan

BRIEF-Sonnet Biotherapeutics Files For Offering Of Up To 2 Million Shares Of Common Stock

Reuters
·
23 Jan

Sonnet Biotherapeutics Holdings Inc Files for Offering of up to 2.0 Mln Shares of Common Stock by the Selling Securityholder - SEC Filing

THOMSON REUTERS
·
23 Jan

Sonnet BioTherapeutics expands Phase 1 SB101 trial

TIPRANKS
·
21 Jan

Sonnet Biotherapeutics Holdings Inc - Topline Safety Data Expected in H2 2025

THOMSON REUTERS
·
21 Jan

Sonnet Biotherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of Son-1010 With Trabectedin in Certain Sarcomas

THOMSON REUTERS
·
21 Jan

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

GlobeNewswire
·
21 Jan

Sonnet Biotherapeutics Files Prospectus Related to Potential Offer, Sale From Time to Time by Chardan Capital Markets Llc of up to 625,000 Shares of Common Stock

THOMSON REUTERS
·
21 Jan

Sonnet Biotherapeutics Announces Release of the Next CEO Corner Segment

THOMSON REUTERS
·
23 Dec 2024

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

GlobeNewswire
·
23 Dec 2024

Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
20 Dec 2024

Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
17 Dec 2024

Sonnet BioTherapeutics FY 2024 GAAP EPS $(11.35)

Benzinga
·
17 Dec 2024